European Commission Approves J&J's Tecvayli Monotherapy for Multiple Myeloma From First Relapse

Johnson & Johnson said on Oct. 23 that the European Commission has extended the marketing authorization for Tecvayli (teclistamab), allowing the subcutaneous bispecific antibody to be used on its own in adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The decision, announced from the company's Beerse, Belgium, base, moves the drug from a late-line option into the first-relapse setting across the European Union and replaces the monotherapy indication and dosing schedule that had applied since 2022.

Treatment background

Multiple myeloma is a cancer of plasma cells in the bone marrow. Most patients respond to initial therapy, but the disease usually returns, and each relapse tends to be harder to control. Johnson & Johnson cited figures showing that more than 35,000 people in the EU were diagnosed with the disease in 2024 and more than 21,900 died from it.

Teclistamab binds B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, steering the patient's own immune cells toward the tumor. The Commission first cleared it in August 2022 for patients who had already received at least three prior therapies. In August 2026, it approved teclistamab in combination with daratumumab as early as the second line. The new decision covers teclistamab used alone in the same earlier setting.

MajesTEC-9 enrolled 614 patients who had received one to three prior lines of therapy, including an anti-CD38 antibody and lenalidomide. They were randomized to teclistamab or to investigator's choice of pomalidomide, bortezomib and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd). Median treatment duration was 13.1 months on teclistamab versus 7.0 months in the control arm. Johnson & Johnson filed the Type II variation with the European Medicines Agency on March 10, 2026.

Industry implications

The approval is part of a broader shift in myeloma care, where T-cell-redirecting therapies that once served heavily pretreated patients are being tested and authorized at first relapse. A positive overall survival result against active standard regimens is a strong data point for that shift, because earlier-line approvals often rest on progression-free survival alone.

For prescribers, the practical change is choice within one product. Physicians in Europe can now use teclistamab either with daratumumab or as a single agent after one prior line, depending on what a patient has already received. MajesTEC-9 specifically enrolled patients previously exposed to an anti-CD38 antibody and lenalidomide, a group that is growing as those drugs move into frontline treatment.

The safety data will shape how fast adoption moves. Nearly all patients in both arms had adverse events, grade 3 or 4 events were more common with teclistamab (84.9% versus 76.3%), and grade 5 events occurred in 6.5% versus 3.5%. Infection prevention and monitoring will remain central to how hospitals deploy the therapy.

Competitive and supply chain implications

Teclistamab competes for BCMA-directed use with other bispecific antibodies, antibody-drug conjugates and CAR-T cell therapies, including Pfizer's Elrexfio, GSK's Blenrep and Johnson & Johnson's own Carvykti, developed with Legend Biotech. An off-the-shelf subcutaneous product with a monthly maintenance schedule offers a different operational profile from personalized cell therapy, which requires collection and manufacturing of a patient's own cells.

Johnson & Johnson is also building a multiple myeloma franchise around combinations. The Committee for Medicinal Products for Human Use issued a positive opinion in October for Talvey (talquetamab), a GPRC5D-directed bispecific, in combination with daratumumab in an earlier line. That would give the company several bispecific regimens anchored by its own anti-CD38 antibody.

The extended monthly dosing option matters for infusion-center capacity and drug supply planning. Fewer clinic visits per patient over the long maintenance phase can ease scheduling pressure on hematology units, while broader eligibility increases the volume of biologic product that must reach treatment centers across the bloc.

Regional implications

A Commission decision is valid in all EU member states as well as Iceland, Liechtenstein and Norway. Actual patient access, however, depends on national pricing and reimbursement reviews, which vary widely in speed. Germany typically makes new indications available soon after approval, while other markets can take a year or longer to complete health technology assessments.

The regulatory sequence also differs by region. The U.S. Food and Drug Administration approved teclistamab with daratumumab for second-line use in March 2026, according to Pharmaphorum. Johnson & Johnson described its EMA monotherapy filing as the first of several planned global submissions but has not disclosed other agencies or dates.

What comes next

• National pricing and reimbursement decisions across EU and EEA markets will determine when patients can receive teclistamab monotherapy at first relapse.
• A European Commission decision on talquetamab plus daratumumab is expected to follow the CHMP's October opinion.
• Johnson & Johnson plans further regulatory filings for teclistamab monotherapy outside Europe; timing has not been disclosed.
• Longer follow-up from MajesTEC-9 and MajesTEC-3 should clarify durability of response and late infection risk.
• Competing BCMA-directed products are pursuing earlier-line data that could reshape treatment sequencing.

Sources

• Johnson & Johnson: European Commission approves Tecvayli monotherapy from first relapse (Oct. 23, 2026)
• Johnson & Johnson: Tecvayli monotherapy application submitted to the EMA (March 10, 2026)
• Johnson & Johnson: CHMP recommends Talvey plus daratumumab in earlier-line myeloma
• Pharmaphorum: J&J scores EU approval for Tecvayli combo in second line (Aug. 21, 2026)

Image: Janssen Pharmaceutica site in Geel, Belgium, by Hoebele via Wikimedia Commons, CC BY-SA 4.0. Cropped and edited by Credence Research.